These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22462748)

  • 1. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
    Li J; Menard V; Benish RL; Jurevic RJ; Guillemette C; Stoneking M; Zimmerman PA; Mehlotra RK
    Pharmacogenomics; 2012 Apr; 13(5):555-70. PubMed ID: 22462748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
    AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
    Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
    Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
    J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.
    Mehlotra RK; Bockarie MJ; Zimmerman PA
    Br J Clin Pharmacol; 2007 Sep; 64(3):391-5. PubMed ID: 17391322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
    Čolić A; Alessandrini M; Pepper MS
    Drug Metab Rev; 2015 May; 47(2):111-23. PubMed ID: 25391641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.
    Mehlotra RK; Bockarie MJ; Zimmerman PA
    Eur J Clin Pharmacol; 2007 Jan; 63(1):1-8. PubMed ID: 17115150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
    Klein K; Lang T; Saussele T; Barbosa-Sicard E; Schunck WH; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2005 Dec; 15(12):861-73. PubMed ID: 16272958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.
    Davaalkham J; Hayashida T; Tsuchiya K; Gatanaga H; Nyamkhuu D; Oka S
    Drug Metab Dispos; 2009 Oct; 37(10):1991-3. PubMed ID: 19581387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
    Carr DF; la Porte CJ; Pirmohamed M; Owen A; Cortes CP
    J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
    Powers V; Ward J; Gompels M
    HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
    Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.
    Svärd J; Spiers JP; Mulcahy F; Hennessy M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):536-49. PubMed ID: 20861742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.